Sandoz, a global leader in generic and biosimilar medicines, has taken a strategic step towards capitalizing on the growing biosimilar market by signing a non-binding term sheet with Evotec SE. This agreement sets the stage for Sandoz to potentially acquire Just-Evotec Biologics (JEB) and its cutting-edge biologics development and manufacturing facility in Toulouse, France.
The acquisition aligns perfectly with Sandoz’s goal of enhancing its in-house biosimilar capabilities and gaining strategic flexibility in the ever-expanding biotech landscape. The proposed transaction, valued at around USD 300 million, would not only strengthen Sandoz’s position in the biosimilar market but also enable the company to leverage JEB’s state-of-the-art technology platform for integrated development and advanced continuous manufacturing.
Read more from manilatimes.net